表紙
市場調查報告書

呼吸道融合病毒(RSV):機會分析與2028年為止的預測

Respiratory Syncytial Virus: Opportunity Analysis and Forecasts to 2028

出版商 GlobalData 商品編碼 915012
出版日期 內容資訊 英文 170 Pages
訂單完成後即時交付
價格
呼吸道融合病毒(RSV):機會分析與2028年為止的預測 Respiratory Syncytial Virus: Opportunity Analysis and Forecasts to 2028
出版日期: 2019年07月31日內容資訊: 英文 170 Pages
簡介

呼吸道融合病毒(RSV)於1956年發現,成為幼兒下呼吸道感染疾病的主要原因,也成為還有老年人的住院和死亡的主要原因 。

本報告提供呼吸道融合病毒(RSV)市場相關調查,疾病的概要與目前治療方法,未滿足需求與機會評估,研究開發策略等相關資訊彙整。

第1章 圖表

第2章 摘要整理

第3章 簡介

第4章 疾病概要

  • 病因與病理學

第5章 流行病學

第6章 目前治療方法

第7章 未滿足需求與機會評估

  • 概要
  • 改善的成本效益高的被動預防法
  • 疫苗接種
  • 有效治療用抗病毒藥物
  • 長期的後遺症的研究和認識

第8章 研究開發策略

  • 概要
  • 臨床實驗設計

第9章 開發平台評估

  • 概要
  • 創新的早期方法
  • 開發中的其他藥物

第10章 開發平台價值評估

  • 臨床基準
  • 商業基準
  • 競爭評估
  • top line10年預測

第11章 附錄

目錄
Product Code: GDHC094POA

Human respiratory syncytial virus (RSV) is an enveloped, single-stranded, negative-sense RNA orthopneumovirus belonging to the family of Paramyxoviridae. The virus was discovered in 1956, first as an isolate from a laboratory chimpanzee displaying symptoms of the common cold, and later from infants suffering from respiratory disease.

The most common clinical scenario for RSV is an upper respiratory tract infection which is typically mild and self-limiting. However, RSV is the leading cause of lower respiratory tract infections (LRTIs) in infants, with a peak age of hospitalization between 2-3 months of age. Severe respiratory disease can manifest as bronchiolitis and pneumonia, which can progress to respiratory failure or death in rare occasions. RSV is also an important cause of hospitalizations and deaths in elderly adults.

The burden of RSV-associated illness is well known; however, challenges stemming from both product and clinical trial design have resulted in several high-profile product failures across all classes of agents including antivirals and prophylactic vaccines and antibodies. Further, the RSV market has seen contraction as the only approved prophylactic antibody, AbbVie and AstraZeneca's Synagis (palivizumab), received an updated recommendation from the American Academy of Pediatrics (AAP) in 2014 for a more narrow population than the antibody is labeled for (i.e., pediatric patients at increased risk of hospitalization due to RSV). These difficulties have limited options for patients currently at risk for complications due to RSV; however, they have driven strong developer interest in addressing RSV across multiple therapeutic avenues.

Key Questions Answered:

  • How will the RSV therapeutic market landscape in the 7MM (US, France, Germany, Italy, Spain, UK, Japan) change from 2018-2028?
  • What are the most promising late-stage pipeline drugs for RSV?
  • How do the clinical and commercial attributes of late-stage pipeline therapies compare with one another, and against existing treatment options?
  • What are the remaining unmet needs in RSV treatment management?
  • What drivers and barriers will affect RSV therapeutics sales in the 7MM over the forecast period?

Scope:

  • Overview of RSV, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.
  • Topline RSV market revenue from 2018-2028. Annual cost of therapy (ACOT) and major pipeline product sales in this forecast period are included.
  • Key topics covered include current treatment and prophylactic options, unmet needs and opportunities, and the drivers and barriers affecting RSV therapeutics sales in the 7MM.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.
  • Analysis of the current and future market competition in the global RSV therapeutics and prophylactics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy:

The report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global RSV market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the RSV therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Respiratory Syncytial Virus: Executive Summary

  • 2.1. Strong Growth Projected for the RSV Market from 2018 to 2028
  • 2.2. Both Large and Small Developers Are Focused on the Untapped RSV Therapeutics Market
  • 2.3. The Market for Cost-Effective RSV Prophylaxis Is Highly Competitive
  • 2.4. Despite Projected Entrance of Novel Products, Opportunities Remain for Current and Future Players
  • 2.5. Future RSV Management Strategies Will Include Multiple Products
  • 2.6. What Do Physicians Think?

3. Introduction

  • 3.1. Catalyst
  • 3.2. Related Reports
  • 3.3. Upcoming Related Reports

4. Disease Overview

  • 4.1. Etiology and Pathophysiology
    • 4.1.1. Etiology
    • 4.1.2. Pathophysiology

5. Epidemiology

  • 5.1. Disease Background
  • 5.2. Risk Factors and Comorbidities
  • 5.3. Global and Historical Trends
  • 5.4. Forecast Methodology
    • 5.4.1. Sources Used and Not Used
    • 5.4.2. Forecast Assumptions and Methods
  • 5.5. Epidemiological Forecast for RSV Hospitalized Population (2018-2028)
    • 5.5.1. Number of Hospitalized Adults with Positive RSV Test
    • 5.5.2. Number of Children Hospitalized for RSV
  • 5.6. Epidemiological Forecast for RSV Prophylactic Population (2018-2028)
    • 5.6.1. Number of Preterm Births by Gestational Age
    • 5.6.2. Premature Infants with CLD
    • 5.6.3. Number of Live Births with Hemodynamically Significant Heart Disease
    • 5.6.4. Diagnosed Prevalent Cases of DMD
    • 5.6.5. Number of Diagnosed Prevalent Cases of SMA
    • 5.6.6. Number of Third Trimester Pregnant Women
    • 5.6.7. Number of Adults Living in Nursing Homes/Long-Term Care Institutions
  • 5.7. Discussion
    • 5.7.1. Epidemiological Forecast Insight
    • 5.7.2. Limitations of Analysis
    • 5.7.3. Strengths of Analysis

6. Current Treatment Options

  • 6.1. Overview

7. Unmet Needs and Opportunity Assessment

  • 7.1. Overview
  • 7.2. Improved Cost-Effective Passive Prophylaxis
    • 7.2.1. Unmet Need
    • 7.2.2. Gap Analysis and Opportunity
  • 7.3. Prophylactic Vaccines
    • 7.3.1. Unmet Need
    • 7.3.2. Gap Analysis and Opportunity
  • 7.4. Effective Therapeutic Antivirals
    • 7.4.1. Unmet Need
    • 7.4.2. Gap Analysis and Opportunity
  • 7.5. Increased Research and Awareness of Long-term Sequela
    • 7.5.1. Unmet Need
    • 7.5.2. Gap Analysis and Opportunity

8. R&D Strategies

  • 8.1. Overview
    • 8.1.1. Development of RSV Antiviral Therapeutics with Diverse Mechanisms of Action
    • 8.1.2. Leveraging Novel Vaccine Technologies and Strategies
    • 8.1.3. Development of Prophylactic Antibodies with Improved Dosing and Efficacy
  • 8.2. Clinical Trials Design
    • 8.2.1. Clinical Trials Design of Pipeline Prophylactics for Maternal Immunization
    • 8.2.2. Clinical Trials Design of Pipeline Prophylactics for Pediatric Immunization
    • 8.2.3. Clinical Trials Design of Pipeline Prophylactics for Adult Immunization
    • 8.2.4. Demonstration of Efficacy for Fusion Inhibitor Antivirals
    • 8.2.5. Demonstration of Efficacy for Replication Inhibitor Antivirals

9. Pipeline Assessment

  • 9.1. Overview
    • 9.1.1. Recently Discontinued Pipeline Products
  • 9.2. Innovative Early-Stage Approaches
  • 9.3. Other Drugs in Development

10. Pipeline Valuation Analysis

  • 10.1. Clinical Benchmark of Key Pipeline Drugs
    • 10.1.1. Therapeutic Agents
    • 10.1.2. Prophylactic Agents
  • 10.2. Commercial Benchmark of Key Pipeline Drugs
    • 10.2.1. Therapeutic Agents
    • 10.2.2. Prophylactic Agents
  • 10.3. Competitive Assessment
    • 10.3.1. Therapeutic Agents
    • 10.3.2. Prophylactic Agents
  • 10.4. Top-Line 10-Year Forecast
    • 10.4.1. US
    • 10.4.2. 5EU
    • 10.4.3. Japan

11. Appendix

List of Tables

  • Table 1: Respiratory Syncytial Virus: Key Metrics in the 7MM
  • Table 2: Risk Factors for Severe RSV
  • Table 3: Treatment Guidelines for RSV
  • Table 4: Leading Treatments for RSV, 2019
  • Table 5: Clinical Trial Designs for RSV Vaccines for Maternal Immunization
  • Table 6: Clinical Trial Designs for RSV Prophylactics for Pediatric Patients
  • Table 7: Clinical Trial Designs for RSV Prophylactics for Adult Patients
  • Table 8: Clinical Trial Designs for RSV Fusion Inhibitor Therapeutics
  • Table 9: Clinical Trial Designs for RSV Replication Inhibitor Therapeutics
  • Table 10: Innovative Early Stage Approaches for RSV, 2019
  • Table 11: Drugs in Development for RSV, 2019
  • Table 12: Clinical Benchmark of Key Pipeline Therapeutics
  • Table 13: Clinical Benchmark of Key Pipeline Prophylactics - RSV mAbs
  • Table 14: Clinical Benchmark of Key Pipeline Prophylactics - RSV Vaccines
  • Table 15: Commercial Benchmark of Key Pipeline Therapeutics
  • Table 16: Commercial Benchmark of Key Pipeline Prophylactics - RSV mAbs
  • Table 17: Commercial Benchmark of Key Pipeline Prophylactics - RSV Vaccines
  • Table 18: Key Events Impacting Sales for RSV, 2018-2028
  • Table 19: RSV Market - Global Drivers and Barriers, 2018-2028
  • Table 20: Key Historical and Projected Launch Dates for RSV
  • Table 21: Key Historical and Projected Patent Expiry Dates for RSV
  • Table 22: High-Prescribing Physicians (Non-KOLs) Surveyed, By Country

List of Figures

  • Figure 1: Global Sales Forecast by Country for RSV in 2018 and 2028
  • Figure 2: Competitive Assessment of Pipeline Therapeutics Benchmarked Against Janssen's Experimental Antiviral JNJ-53718678
  • Figure 3: Competitive Assessment of the Marketed and Pipeline Prophylactics Benchmarked Against AstraZeneca's Synagis
  • Figure 4: Structure of the Human RSV Virion
  • Figure 5: Replication Cycle of RSV
  • Figure 6: 7MM, Children, Boys and Girls, 0-2 Years Old, Confirmed RSV Hospitalizations, N, 2008-2018
  • Figure 7: 7MM, Rate of Preterm Births (per 1,000 Live Births), 2008-2018
  • Figure 8: 7MM, Percentage of Adults Living in Long-Term Care, Ages ≥55 Years, 2008-2018
  • Figure 9: 7MM, Sources Used to Forecast the Number of Adults Hospitalized Who Test Positive for RSV, 2018-2028
  • Figure 10: 7MM, Sources Used to Forecast the Number of Children Hospitalized with Confirmed RSV
  • Figure 11: 7MM, Sources Used to Forecast the Number of Preterm Births
  • Figure 12: 7MM, Sources Used to Forecast the Number of Preterm Births with CLD, 2018-2028
  • Figure 13: 7MM, Sources Used to Forecast the Number of Live Births with Hemodynamically Significant Heart Disease
  • Figure 14: 7MM, Sources Used to Forecast Diagnosed Prevalent Cases of DMD
  • Figure 15: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of SMA
  • Figure 16: 7MM, Sources Used to Forecast the Number of Third Trimester Pregnancies
  • Figure 17: 7MM, Sources Used to Forecast the Number of Adults Living in Long-Term Care
  • Figure 18: 7MM, Number of Hospitalized Adults, Ages ≥60 Years, with Positive RSV Test, Men and Women, 2018
  • Figure 19: 7MM, Number of Children, Ages 0-2 Years, Boys and Girls, Hospitalized for RSV, 2018
  • Figure 20: 7MM, Number of Preterm Births by Gestational Age, N, 2018
  • Figure 21: 7MM, Number of Preterm Infants with CLD, N, 2018-2028
  • Figure 22: 7MM, Number of Live Births with Hemodynamically Significant Heart Disease, 2018-2028
  • Figure 23: 7MM, Diagnosed Prevalent Cases of DMD in Boys, Ages 0-2 Years, 2018-2028
  • Figure 24: 7MM, Diagnosed Prevalent Cases of SMA, Boys and Girls, Ages 0-2 Years, 2018-2028
  • Figure 25: 7MM, Number of Third Trimester Pregnant Women, N, 2018-2028
  • Figure 26: 7MM, Number of Adults Living in Care Institutions, Ages ≥55 Years, N, 2018-2028
  • Figure 27: Unmet Needs and Opportunities in RSV
  • Figure 28: Overview of the Development Pipeline in RSV
  • Figure 29: Key Phase II/III Trials for the Promising Pipeline Agents that GlobalData Expects to Be Licensed for RSV in the 7MM During the Forecast Period
  • Figure 30: Competitive Assessment of Pipeline Antivirals
  • Figure 31: Competitive Assessment of Pipeline Prophylactics Benchmarked Against the Current SOC
  • Figure 32: Global (7MM) Sales Forecast by Country for RSV in 2018 and 2028
  • Figure 33: Global Sales Forecast by Product for RSV in 2028
  • Figure 34: Therapeutic Sales Forecast by Product for RSV in the US from 2018 to 2028
  • Figure 35: Prophylactic Sales Forecast by Class for RSV in the US from 2018 to 2028
  • Figure 36: Therapeutic Sales Forecast by Product for RSV in the 5EU from 2018 to 2028
  • Figure 37: Prophylactic Sales Forecast by Class for RSV in the 5EU from 2018 to 2028
  • Figure 38: Therapeutic Sales Forecast by Product for RSV in Japan from 2018 to 2028
  • Figure 39: Prophylactic Sales Forecast by Class for RSV in Japan from 2018 to 2028